Multinational pharma main Pfizer has arrange a worldwide drug growth centre in Chennai, the primary and solely facility in Asia for the corporate which can develop merchandise for world markets and assist the corporate’s manufacturing centres worldwide.
The centre’s capabilities will embrace the event of each energetic pharmaceutical components (APIs) and completed dosage varieties (FDFs) of differentiated merchandise resembling advanced, value-added formulations, controlled-release dosage varieties, device-combination merchandise, lyophilised injections, powder-fill merchandise, and ready-to-use formulations.
Pfizer has invested $20 million (Rs 150 crore) for the 61,000 sq ft analysis and know-how centre on the IIT Madras Research Park. While this centre can be part of a community of 12 world centres arrange worldwide, it’s the first and just one at current being arrange by Pfizer in Asia.
Speaking to pick out journalists, S Sridhar, nation supervisor, Pfizer India, mentioned that the Chennai centre will primarily give attention to growing small molecules, revolutionary formulations and APIs for world markets.
“Pfizer’s drug development centre in the IIT Madras Research Park is a positive opportunity to establish truly one of the most advanced laboratories that Pfizer is setting up for R&D in the aforementioned disciplines anywhere in the world, in Chennai and an opportunity to showcase the potential of R&D in the country,” he mentioned.
The centre integrates two important capabilities below the export-oriented endeavor of Pfizer particularly pharmaceutical sciences (PharmSci) and world know-how and engineering (GT&E) centre of excellence. PharmSci is devoted to the event of anti-infectives, oncolytics, sterile injectables, anesthesia merchandise, CNS merchandise, and uniquely differentiated hospital merchandise. GT&E pioneers next-generation API course of and manufacturing know-how to produce medicines to sufferers across the globe.
“We are confident that it will allow for synergistic co-development of cutting-edge API and FDF processes under the same roof. The world-class scientific, technology and innovation-driven Research Park campus provides an ideal setting for our work. We are hopeful that the proximity to IIT Madras and other technology Research Park start-ups will also improve academia and industry partnerships and encourage greater collaboration to drive innovation,” he mentioned.
The 61,000 sq ft facility will make use of 250 scientists and professionals from a spread of scientific disciplines together with formulation scientists and pharmacists, analytical scientists with experience in course of, analytical and formulation medicinal sciences, life science specialists resembling microbiologists and biotechnologists, chemical engineers, information scientists and programme managers.
The centre, which has 10 laboratories, will develop advanced sterile injectable formulations and gadget mixture merchandise for hospital phase, together with anti-infectives and oncolytics.
Source: www.financialexpress.com”